Pozen.

PositionTRIANGLE

CHAPEL HILL -- Drug developer Pozen and British drug manufacturing giant AstraZeneca struck a deal that could be worth $375 million to Pozen. It will get an upfront payment of $40 million for the development of an arthritis treatment...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT